Skip to main content
Forte Biosciences, Inc. logo

Forte Biosciences, Inc. — Investor Relations & Filings

Ticker · FBRX ISIN · US8888461022 LEI · 529900Z84WFDHPS3JP76 US Manufacturing
Open in API
Filings indexed 507 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country US United States of America
Listing US FBRX

About Forte Biosciences, Inc.

https://www.fortebiorx.com/home/default…

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and autoimmune-related diseases. The company's lead product candidate is FB-102, a proprietary molecule with potentially broad applications. Forte is advancing FB-102 through clinical trials for several indications, including celiac disease, vitiligo, and alopecia areata.

Recent filings

Filing Released Lang Actions
S-3
Regulatory Filings Classification · 82% confidence The document is a Form S-3 registration statement and prospectus filed with the SEC under the Securities Act of 1933 for a shelf offering up to $500 million. It is neither an annual report (10-K), an earnings release, nor a management discussion, nor a proxy or dividend notice. It is not a board change notice or M&A filing. Since there is no dedicated category for SEC registration statements in the taxonomy, it falls under the generic “Regulatory Filings” (RNS) category for miscellaneous compliance and regulatory documents.
2026-06-02 English
S-8
Share Issue/Capital Change Classification · 94% confidence The document is a Form S-8 registration statement filed with the SEC under the Securities Act of 1933 to register new shares of common stock for employee stock plans. Form S-8 is used to register employee benefit plan shares, which constitutes a change in the company’s capital structure. This falls squarely under the “Share Issue/Capital Change” category.
2026-06-02 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 83% confidence The document is a Form 8-K current report filed with the SEC under the Securities Exchange Act of 1934. The substantive content includes Item 5.07 “Submission of Matters to a Vote of Security Holders,” providing detailed vote counts for proposals at the 2026 Annual Meeting of stockholders. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-06-02 English
8-K
Earnings Release Classification · 88% confidence The document is a Form 8-K Current Report filed under Item 2.02 “Results of Operations and Financial Condition” which furnishes a press release with the company’s quarterly financial results for the quarter ended March 31, 2026. This is the initial announcement of periodical financial results, fitting the “Earnings Release” category. Q1 2026
2026-05-14 English
424B5 - Forte Biosciences, Inc. (0001419041) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and company overview. The document is clearly a capital raising filing, describing the terms of a stock offering and related disclosures. It is not an annual report, earnings release, or management discussion, nor is it a regulatory filing unrelated to capital raising. The presence of underwriting details, offering price, shares offered, and related information confirms this is a Capital/Financing Update filing.
2026-04-09 English
8-K - Forte Biosciences, Inc. (0001419041) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 8, 2026, by Forte Biosciences, Inc. It reports the entry into a material definitive agreement related to an underwriting agreement for a public offering of common stock. The document details the terms of the offering, expected proceeds, and related legal opinions. It also includes a press release about the pricing of the offering. The content focuses on a capital raising event and financing activities. There are no financial statements or quarterly/yearly financial results presented, nor is it a transcript, management report, or governance document. The primary subject is the update on the company's financing activity through a stock offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (8121 characters) and detailed content support this classification with high confidence.
2026-04-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.